Search Results
Non-Hodgkin Lymphoma 3D Model
.model-icon-key-mobile{ display:none;} @media only screen and (max-width: 767px) { .model-icon-key-desktop{ display: none;} .model-icon-key-mobile{ display: block;} }This model contains the following chapters. Click the "Interact in 3D" button to begin.
- Healthy Bone Marrow
- Normal Blood Cell Production
- Proliferation of Cells and the Crowding Out of Normal Cells
- Signs and Symptoms
Insurance Inequities in Hodgkin Lymphoma Treatment and Survivorship in the Southeast
Black and Hispanic individuals diagnosed with Hodgkin lymphoma (HL) face worse survival rates across all ages. Using an innovative data source, this study will examine differences by insurance status in the receipt and quality of HL treatment in Aim 1 and care engagement and support after treatment (survivorship care) in Aim 2. Using diverse patient voices, this study will characterize and understand how patients make decisions about treatment and survivorship care by insurance type in Aim 3.Tisagenlecleucel
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of
Loncastuximab
Loncastuximab tesirine-lpyl is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Pralatrexate
Pralatrexate is FDA approved to treat people who have relapsed or refractory peripheral T-cell lymphoma. It is being studied to treat people who have other forms of lymphoma including diffuse large B-cell lymphoma.
Exploiting escape from Y-inactivation as a synthetic dependency in MYC-driven lymphoma
As a lymphoma develops it expresses genes that are normally silenced to convey a survival advantage. When these genes are on the X or Y (sex chromosomes) they may present a gender-specific therapeutic target. We have identified a gene (DDX3X in females or DDX3Y in males) that is reactivated in lymphomas such that the lymphomas cannot survive if this gene is removed. This project will develop new ways to inhibit DDX3X and Y as a novel treatment for poor-risk and aggressive lymphoma.Investigating the role of CREBBP mutations and epigenetic crosstalk in B-cell lymphoma
We seek to understand the genetic and epigenetic etiology of B-cell lymphoma and how deregulation of normal epigenetic programs perturb developmental programs and immune interactions. We approach this using a variety of genomic technologies to interrogate primary human tumors, CRISPR-engineered cell lines, patient-derived xenograft models and transgenic mouse models with different genetic lesions.Cellular and genetic drivers of Cutaneous γδ T-cell lymphomas (PCGDTL)
Primary cutaneous γδ T-cell lymphoma (PCGDTL) is a rare type of lymphoma caused by the rare types of T-cells called γδ T-cells (most T cells in our body in αβ T-cells). The disease usually shows symptoms in the skin, thus it is also considered a rare type of skin cancer. The disease is very aggressive. After diagnosis patients may die within 3 months. Only about 10% patients are alive after 5 years. However, little is known about the disease. For the last two decades, most knowledge has been generated with a handful of patient samples.
Blood Cancer Research Poised for Another ‘Banner Year’ in 2024
More than 25,000 medical professionals from across the world came together in December to discuss the latest blood cancer developments during the annual meeting of the American Society of Hematology (ASH). This annual event gives us the opportunity to think about what advances are on the horizon as LLS works to strengthen cures, care and quality of life for people with blood cancer and their families.
Glofitamab-gxbm
Glofitamab-gxbm is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy.
Zanubrutinib
Zanubrutinib is indicated for the treatment of adult patients with:
Translating molecular profiles into treatment approaches to target disparities in lymphoma
Although many patients with diffuse large B-cell lymphoma (DLBCL) are cured with standard therapy, others will die from their disease. Survival is significantly worse for African American (AA) patients and those with Epstein- Barr virus (EBV), which is common in patients from Latin America. The reasons behind these poor outcomes are not well understood, in part because most studies of molecular features in lymphomas have not included enough patients from these racial and ethnic groups.Tazemetostat
Tazemetostat is a methyltransferase inhibitor indicated for the treatment of:
Relevance of ubiquitin dependent proteolysis in Diffuse Large B-cell lymphoma
The goal of this proposal is to investigate the significance of genes of the ubiquitin proteasome system (UPS) that are mutated in Diffuse Large B-cell Lymphoma (DLBCL). Our studies leverage the expertise in the molecular modeling of the UPS in the pathogenesis of DLBCL utilizing mouse models, patient derived xenotransplant (PDX) and cell lines. Our goal is the understanding of how genetic mutations contribute to disease development, progression and therapeutic outcome.World-Renowned Chef & Cancer Survivor Cooks for a Cure
Shortly before Steve McHugh and his wife moved to San Antonio in 2010, the rising star chef was diagnosed with non-Hodgkin lymphoma and spent a year undergoing eight rounds of chemotherapy.
“Chemotherapy was a real roller coaster – I experienced insomnia, constipation and dizzy spells. There were times I would not sleep for three to four days,” he said.
Novel Immunotherapy Combinations in Relapsed, Refractory Mantle Cell Lymphoma
We are evaluating two parallel clinical trials with synergistic immunotherapies in mantle cell lymphoma (MCL), including 1) tafasitamab and lenalidomide and 2) glofitamab and lenalidomide. We will investigate how these treatments impact the MCL immune microenvironment and mediate anti-tumor immune responses, and will correlate these changes with outcome. Our goal is to develop safe, effective, and "off-the-shelf" immunotherapies to improve outcomes for patients with relapsed, refractory MCL.
Immunotherapies on a Roll at #ASH20
More than three years after the first chimeric antigen receptor (CAR) T-cell therapy achieved U.S. Food and Drug Administration (FDA) approval, the revolutionary approach that has upended blood cancer treatment continues to generate excitement.